[RESEARCH BLOG] · 2026-07-31
Viemed Healthcare (VMD) – Sell Signal Amid Bull Market Regime, Q2 Outlook in Focus
By Pierre Brunelle · Founder & Research Lead
VMD closed at $11.76, up 0.94% as of 2026‑07‑30 (Thursday, US session). The LOPJLB proprietary scanner has issued a SELL directional signal with a ‑5 score while the broader market remains in a BULL regime.
Viemed Healthcare Announces Second Quarter 2026 Earnings Conference Call Details announced the schedule for its second‑quarter 2026 earnings conference call on July 21, confirming that management will discuss results on the upcoming call and provide updates on its home‑medical‑equipment (HME) and post‑acute respiratory services portfolio. The notice, posted on Access Newswire, underscores the company’s continued focus on transparent investor communication amid a volatile healthcare environment.
A comparative analysis published by The Motley Fool on June 10 evaluated Viemed against Surgery Partners, arguing that while both firms operate in the outpatient‑care space, Viemed’s higher revenue growth rate (23% YoY in 2025) and stronger free‑cash‑flow yield (5.75%) give it a modest edge. The article, however, cautioned that Viemed’s valuation—trailing P/E of 30.38 and forward P/E of 21.82—remains elevated relative to peers, suggesting limited upside unless earnings accelerate further. See the full piece: Surgery Partners vs. Viemed Healthcare: Which Outpatient Care Stock Is a Better Buy in 2026?
Stonegate Capital Partners Updates Coverage on Viemed Healthcare, Inc. (VMD) 1Q26 released an updated coverage note on May 12, highlighting that Viemed’s 2025 revenue of $270.3 M represents a 23.1% year‑over‑year increase, while earnings per share rose to $0.38. The analyst team reiterated a Buy recommendation but flagged a potential downside risk from rising debt levels, noting a debt‑to‑equity ratio of 8.65 and an interest‑coverage ratio of 18.36.
Viemed Healthcare, Inc. (VMD) Q1 2026 Earnings Call Transcript made available by Seeking Alpha on May 6 revealed that management cited strong demand for non‑invasive ventilation devices, especially in the chronic obstructive pulmonary disease (COPD) segment. Executives emphasized that the company’s operating margin held steady at 8.38%, despite a modest dip in net margin to 5.20%. The discussion also touched on ongoing supply‑chain constraints that could pressure inventory turnover in the second half of the year.
Viemed Healthcare, Inc. (VMD) Q1 Earnings Miss Estimates reported on May 5 that Viemed missed consensus estimates for Q1 earnings, posting an EPS of $0.29 versus the expected $0.31. Revenue of $224.3 M fell short of the consensus forecast of $229 M, prompting a brief downgrade of the analyst’s rating outlook. The report noted that while the miss was modest, it added pressure to the stock’s momentum heading into the Q2 reporting window.
Viemed Healthcare Announces First Quarter 2026 Financial Results announced its first‑quarter 2026 financial results, confirming the $224.3 M revenue figure and a free‑cash‑flow generation of $1.32 M. The company highlighted a 5.75% free‑cash‑flow yield and a 3.29% buyback yield, underscoring its commitment to returning capital to shareholders despite the recent earnings miss.
Fundamentals and Valuation
Viemed Healthcare trades at a trailing P/E of 30.38 and a forward P/E of 21.82, indicating that the market currently prices the stock at roughly 30 times its most recent twelve‑month earnings and anticipates a modest earnings improvement over the next twelve months. The EV/EBITDA multiple of 8.55 places the company in line with mid‑range healthcare peers, while the EV/EBIT ratio of 18.88 suggests a higher valuation relative to operating income.
The firm’s price‑to‑book (P/B) ratio of 3.14 reflects a premium over book value, consistent with its growth‑oriented profile. A price‑to‑free‑cash‑flow (P/FCF) of 17.39 aligns with the company’s free‑cash‑flow yield of 5.75%, indicating that cash generation remains a core component of shareholder returns. The PEG ratio of 0.64 signals that earnings growth (21.19% YoY EPS growth) outpaces the price multiple, a characteristic often prized by growth‑oriented investors.
Profitability metrics show a gross margin of 57.32%, a operating margin of 8.38%, and a net margin of 5.20%. While the gross margin remains robust, operating and net margins have compressed modestly from the 2024 levels (operating margin 7.98%, net margin 5.02%). Return metrics are solid: ROIC of 11.41%, ROE of 10.69%, and ROA of 7.55%. These figures exceed the company’s weighted‑average cost of capital, suggesting that Viemed continues to create shareholder value on an economic basis.
Revenue growth has been a defining theme. The company posted $270.3 M in 2025, up 23.1% from the prior year’s $224.3 M. Over the five‑year historical window, revenue rose from $131.3 M in 2020 to $270.3 M in 2025, representing a compound annual growth rate (CAGR) of roughly 24%. EPS has similarly improved, climbing from $0.86 in 2020 to $0.38 in 2025 after a dip in 2022‑2023, reflecting the company’s ability to translate top‑line growth into earnings despite margin pressures.
Free‑cash‑flow generation has been uneven. After a peak of $19.1 M in 2023, FCF fell to $1.32 M in 2024 before rebounding to $11.9 M in 2025. The volatility reflects the capital‑intensive nature of HME inventory and the timing of equipment purchases by healthcare providers. Nonetheless, the current 5.75% FCF yield, combined with a 3.29% buyback yield, underscores a commitment to returning cash to shareholders.
The Altman Z‑score of 7.90 places Viemed well within the “safe zone,” indicating low bankruptcy risk. However, the debt‑to‑equity ratio of 8.65 is high for a growth‑oriented healthcare firm, suggesting that leverage could become a focal point for investors, especially if interest rates rise. The interest‑coverage ratio of 18.36 remains comfortable, but the leverage level warrants monitoring.
Below is a snapshot of key valuation and profitability metrics as of the latest filing:
| Metric | Value |
|---|---|
| Trailing P/E (TTM) | 30.38 |
| Forward P/E | 21.82 |
| EV/EBITDA | 8.55 |
| Gross Margin | 57.32% |
| Operating Margin | 8.38% |
| Net Margin | 5.20% |
| ROIC | 11.41% |
| ROE | 10.69% |
| ROA | 7.55% |
| FCF Yield | 5.75% |
| Buyback Yield | 3.29% |
| Debt/Equity | 8.65 |
| Altman Z‑Score | 7.90 |
The company’s value score of 69, growth score of 73, GARP score of 86.6, and quality score of 88.96 collectively place Viemed in the Growth Compounder archetype, reflecting a blend of solid earnings growth, respectable profitability, and a balance of valuation discipline.
ETF Ownership
Viemed’s institutional exposure is relatively concentrated. Two exchange‑traded funds hold the stock, together accounting for ~1.57% of the float. The largest holder is the S&P SmallCap 600 Health Care ETF (SAWS), which owns 1.39% of VMD’s outstanding shares, ranking the stock at #32 within the fund. The second holder, the iShares MSCI Global Impact ETF (OLD), carries a 0.18% stake, placing VMD at #39 in that portfolio.
While the overall ETF ownership is modest, the presence of SAWS—a fund focused on small‑cap healthcare innovators—adds a layer of sector‑specific demand that could influence short‑term liquidity, especially during earnings windows. The low concentration reduces the risk of a single ETF‑driven price swing, but it also means that broader market sentiment toward healthcare ETFs may have a muted direct impact on VMD’s share price.
LOPJLB Signal Read
The LOPJLB scanner currently flags VMD with a SELL directional signal and a ‑5 composite score, even though the broader market is classified in a BULL regime (45‑day horizon). The signal reflects a combination of momentum and valuation overlays that have turned bearish, despite the underlying bullish market backdrop.
Performance (PERF) and quality (FUND) composites are 55.10 and 88.96, respectively, indicating that while the company scores strongly on quality metrics, its recent price action and relative strength have weakened. The Growth score of 73 and GARP score of 86.6 suggest that the stock still possesses growth attributes, but the Value score of 69 and the negative directional bias imply that the market may be pricing in near‑term headwinds—potentially from the recent earnings miss, elevated leverage, or the upcoming Q2 earnings release.
Viemed fits the Growth Compounder archetype, meaning it historically combines earnings acceleration with solid cash generation. Investors seeking exposure to this profile should review the interactive chart above on the stock page for a visual of the underlying technical overlays, and consult the full methodology at the LOPJLB methodology page for deeper insight into how the signal is derived.
Further Research
- Detailed stock page: https://www.lopjlb.com/stock/VMD
- Earnings archive (if the Q2 call materializes): https://www.lopjlb.com/stock/VMD/earnings.md
- Full‑screen screener for comparable healthcare names: https://www.lopjlb.com/screener
The information presented herein is for research purposes only and does not constitute investment advice. Readers should conduct their own due diligence and consider their individual risk tolerance before making any investment decisions.
This post is independent quantitative research, not investment advice. LOPJLB signals are model outputs derived from price, volume, and fundamentals. Past backtests do not guarantee future results. Position sizing, execution, and risk management remain the reader's responsibility.